65,437 trials
Osteoporosis
Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants
Diabetic Macular Edema
Primary: Number of Participants With Intraocular Inflammation — 6; 10 Participants
Dry Eye Syndrome · Keratoconjunctivitis Sicca
Primary: Acute Stimulated Tear Production — 25.3; 9.2; 9.5 mm
Alcoholism · Alcohol Abuse · Alcohol Dependence
Primary: Heavy Drinking Days Per Week — 1.75; 2.67 heavy drinking days/week — p=0.002
Contraception · Pain
Primary: Patient-reported Pain at Passage of Insertion Device Through Cervix, as Measured on a 100 mm VAS — 55.8; 53.9 mm
Eosinophilic Esophagitis
Primary: Post-Treatment Maximum Eosinophil Count (Aim 1) — 14.7; 20.9 eosinophils per high-power field — p=0.31
Major Depressive Disorder
Primary: Hamilton Depression Rating Scale (HDRS) Scores 24 — 17.88; 19.92; 6.86; 10.33 units on a scale
Japanese Encephalitis · Japanese Encephalitis Vaccine
Primary: Change of T Lymphocyte Responses to Live Attenuated JE SA-14-14-2 Vaccine at Week 2. — 34 IFNγ SFC/million PBMC
Neisseria Gonorrhoeae Infection · Chlamydia Trachomatis Infection · Sexually Transmitted Infections
Primary: Number of Participants With Nucleic Acid Amplification Test (NAAT) 1 Index Test Results Relative to Anatomic Site Infection Status (ASIS) Reference Results for Neisseria…
Cardiac Arrest
Primary: CPR Quality-compression Depth — 46.7; 61.6 mm
Dementia With Lewy Bodies
Primary: Unified Parkinson's Disease Rating Scale-Part III (UPDRS-III) Change From Baseline at Week 24 — -0.55; 1.45; -1.29 units on a scale — p=0.158
Obesity Hypoventilation Syndrome
Primary: Daytime Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2) — 47.1; 51.8; 50.7; 40.7 mmHg
Healthy
Primary: Glutamate + Glutamine (Glx)/Creatine Ratio as Measured by MRS in the Brainstem Pre and Post-Botox — .12 Brainstem GLX/Cr
Metastatic Pancreatic Cancer
Primary: Progression Free Survival With the Combination of GDC-0449 With Gemcitabine and Nab-paclitaxel. — 5.42 months
Non-functioning Pituitary Adenoma
Primary: Percentage of Participants With Non-functioning Pituitary Adenomas (NFPA) Who Achieve Tumor Volume Reduction of at Least 20% After 24 Weeks (FAS) — 16.7 percentage of…